Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare once and twice daily GW685698 in asthma

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Key Inclusion Criteria:

• Clinical diagnosis of Asthma

• Reversibility ≥ 12% and ≥200mls reversibility of FEV1 within approximately 30-minutes following 2 to 4 puffs of albuterol

• FEV1 between 40-85% predicted

• Currently on short acting beta2 agonist therapy

Key Exclusion Criteria:

• History of life threatening asthma

• Respiratory Infection or oropharyngeal candidiasis

• Asthma exacerbation

• Uncontrolled disease or clinical abnormality

• Allergies

• Taking another Investigational medications or other prohibited medications